Tobacco Companies Are Cashing In on Zyn’s Unstoppable Popularity
Tobacco companies are racing to capitalize on the surging popularity of Zyn and other smoke-free alternatives.
📍 The outcome
Nicotine pouches gained traction as a popular smoke-free alternative to cigarettes, driven by a surge in demand among new demographics in the UK. While tobacco companies actively expanded their portfolios to capitalize on the product's growth, health advocates urged the FDA to prioritize public health over corporate profit margins.
The story quieted without a definitive conclusion in the coverage.
Epilogue added 42d ago, after coverage quieted.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Tobacco firms are actively seeking to profit from the widespread growth of Zyn. This shift toward smoke-free products is notably occurring as companies like Philip Morris seek success with both regulators and investors.
Coverage from The New York Times and Barron's emphasizes the financial race to cash in on Zyn's popularity and the market appeal of non-combustible products. Meanwhile, Oncodaily features perspectives from Lisa A.
Lacasse regarding the FDA's role in protecting public health versus the profit margins of big tobacco. Future developments center on whether Philip Morris' smoke-free products continue to win over regulators and investors, and how the FDA manages the balance between public health and industry profitability.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 45d ago.
Who reported it (9)
- The new smoke-free craze GZERO Media · 45d ago
- Haypp Report Shows Nicotine Pouches Gaining Ground as a Vape Alternative in the UK 2Firsts · 45d ago
- Survey Finds 95% Happy Moving from Cigarettes to Pouches Tobacco Reporter · 45d ago
- Haypp Report: Women Emerge as a Key Growth Driver in the UK Nicotine Pouch Market 2Firsts · 45d ago
- Nicotine pouches surge in popularity, report shows Talking Retail · 45d ago
- Zyn’s Popularity Has Tobacco Companies Racing to Cash In NYT > Business · 45d ago
- Lisa A. Lacasse։ The FDA’s Job is to Protect Public Health, Not Expand the Profit Margins of Big Tobacco Oncodaily · 45d ago
- Philip Morris’ Smoke-Free Products Are Winning With Regulators. They’ll Win With Investors Too. Barron's · 45d ago
- Tobacco Companies Are Cashing In on Zyn’s Unstoppable Popularity The New York Times · 45d ago broke it first
The obvious questions
Which companies are mentioned in relation to smoke-free products?
Philip Morris is specifically cited as having smoke-free products that are winning with regulators and investors.
What is the primary driver of the current industry trend?
The unstoppable popularity of Zyn is driving tobacco companies to find ways to cash in.
What is the critique regarding the FDA's role in this trend?
According to Lisa A. Lacasse in Oncodaily, the FDA's objective should be protecting public health rather than expanding the profit margins of big tobacco.
People, places & organizations
Topics
Related trends
US law to investigate foodborne illness outbreaks has been delayed for 15 years
A 15‑year freeze on a key food‑safety law is sparking congressional pressure as groups warn it hinders outbreak investigations.
Marketside soup sold at Walmart recalled over Listeria concerns: FDA
Marketside tomato bisque soup kits face a 29‑state recall over potential Listeria, hitting Walmart shoppers nationwide
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms recalls ready-to-eat foods and jalapeño products over salmonella concerns.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to the drug being described as subpotent.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.